Abstract: Provided herein is a non-invasive biometric sensing and monitoring device that may be employed in a non-invasive method with the potential for comprehensive analysis and data processing. The non-invasive biometric sensing and monitoring device may be employed for determining a characteristic of a state of a wearer using the device based on a value of a biomolecule within a body tissue of the user. The device may include a housing for retaining one or more components of the biometric device. The components may may include a substrate, such as a printed circuit board, and may further include one or more of an signal generator, a microwave structure based sensor unit, a filter unit, a receiver component, an analog to digital converter, a control unit, one or more buffers, a communications module and controller as well as an analytics system.

Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.

Abstract: The present application discloses the use of light-gated cation-selective channelrhodopsins (Ch Rs) for the optogenetic control of the secretion of a polypeptide of interest in adipocytes. Engineered adipocytes comprising a channelrhodopsin (ChR) polypeptide, and/or a nucleic acid encoding same, and a secretory polypeptide precursor comprising a bioactive polypeptide and a signal peptide suitable for secretion of the bioactive polypeptide by the engineered adipocytes, and/or a nucleic acid encoding same, are disclosed. The use of such engineered adipocytes for the management or treatment of diseases/conditions in which the secretion of a polypeptide of interest is beneficial, such as the secretion of insulin in diabetic patients, is also disclosed.